platoseedplatoseed
We use human data and AI to develop better drugs faster.
Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
Verge Genomics is a biotechnology company that uses human data and AI to discover and develop drugs, aiming to move from research to clinic rapidly. It operates an all-in-human, AI-powered platform to map disease biology and generate proprietary drug candidates. The company emphasizes partnerships and a pipeline targeting neurodegenerative and other major diseases.
Verge uses an all-in-human, AI-powered platform (CONVERGE) to build proprietary multi-omics databases from human tissue, map disease causes with machine learning, and develop proprietary drug candidates on internal biology and chemistry platforms. They discover drugs in humans first, moving from research to clinic in accelerated timelines, with internal drug candidates including VRG50635 (a PIKfyve inhibitor for ALS) that has entered the clinic, and a pipeline focused on Parkinson's Disease, Frontotemporal Dementia, and other diseases.
Who it’s for: Biotech/pharma stakeholders seeking AI-driven drug discovery partnerships, pharmaceutical companies, and researchers interested in human-data–driven translational medicine.
has a published pipeline and a drug in clinic (VRG50635 for ALS); mentions partnerships and collaborations; mentions recruitment and careers
Artificial intelligence for drug discovery.
Using AI to predict biochemistry for manufacturing and therapeutics
